¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Oxygen Permeable Lens Products Misc"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® Lens ÇÑ±Û ·»Áî, ¼öÁ¤Ã¼
¼³¸í   
  ´«¼ÓÀÇ Àå±âÁß Çϳª¿¡ ÇØ´ç. °¢¸·À» Åë°úÇÑ ºûÀº ¼öÁ¤Ã¼¸¦ Åë°úÇÏ¿© ¸Á¸·¿¡ »óÀÌ ¸ÎÈ÷°Ô µÇ°í, ¸Á¸·Àº ÀÌ µé¾î¿Â ºûÀ» ÀÚ±ØÀ» ½Å°æ¼¼Æ÷°¡ ¾Ë ¼ö Àִ ½Åȣü°è·Î ¹Ù²Ù¾î ³ú¿¡ Àü´ÞÇØ ÁÖ°Ô µÈ´Ù. °¢¸·°ú ¼öÁ¤Ã¼ÀÇ Áß¿äÇÑ ¿ªÇÒÀº ±¼Àý·ÂÀ» Áõ°¡½Ã۴ °ÍÀÌ´Ù. ±×¸®ÇÏ¿© ¿Ã¹Ù·Î »óÀÌ ¸Á¸·¿¡ ¸ÎÈú ¼ö ÀÖµµ·Ï µµ¿ÍÁÖ°Ô µÈ´Ù.
  
  ·»Áî, ¼öÁ¤Ã¼
¿µ¹® oxygen ÇÑ±Û »ê¼Ò
¼³¸í   
  Æó·Î µé¾î°¡ ¸ð¼¼Ç÷°üÀ» ÅëÇØ ÀûÇ÷±¸³»·Î µé¾î°£´Ù. ÀûÇ÷±¸³»ÀÇ Ç÷»ö¼ÒÀÇ ¿ªÇҷΠ½Åü³» ¸ðµç Á¶Á÷¼¼Æ÷¿¡ ÀüÇØÁö¸ç, ÀÎü´ë»çÀÛ¿ë¿¡ ÇʼöÀûÀΠ±âüÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gas permeable lens
    °¡½ºÅõ°ú·»Áî, »ê¼ÒÅõ°ú·»Áî
  • fibrinogen degradation products
    ¼¶À¯¼Ò¿øºÐÇØ»ê¹°
  • permeable
    Åõ°ú-
  • permeable membrane
    Åõ°ú¸·
  • arterial oxygen saturation
    µ¿¸ÆÇ÷»ê¼ÒÆ÷È­µµ
  • arterial oxygen tension
    µ¿¸ÆÇ÷»ê¼ÒºÐ¾Ð
  • active oxygen
    Ȱµ¿»ê¼Ò, Ȱ¼º»ê¼Ò
  • alveolar oxygen pressure
    ÆóÆ÷»ê¼Ò¾Ð, ÇãÆÄ²Ê¸®»ê¼Ò¾Ð
  • alveolar-arterial oxygen gradient
    ÆóÆ÷µ¿¸Æ°£»ê¼ÒºÐ¾ÐÂ÷
  • biochemical oxygen demand
    »ý¹°È­ÇÐÀû»ê¼Ò¿ä±¸·®
  • biological oxygen demand
    »ý¹°ÇÐÀû»ê¼Ò¿ä±¸·®
  • compressed oxygen
    ¾ÐÃà»ê¼Ò
  • chemical oxygen demand
    È­ÇÐÀû»ê¼Ò¿ä±¸·®
  • dissolved oxygen
    ¿ëÇØ»ê¼Ò
  • dissolved oxygen determination
    ¿ëÁ¸»ê¼Ò·®ÃøÁ¤, ³ìÀº»ê¼Ò·®ÃøÁ¤
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fibrinogen degradation products product
    ¼¶À¯¼ÒºÐÇØ»ê¹°
  • fibrinogen degradation products product
    ¼¶À¯¼Ò¿øºÐÇØ»ê¹°
  • bifocal lens
    ÀÌÁßÃÊÁ¡·»Áî
  • lens
    ¼öÁ¤Ã¼, ·»Áî
  • intraocular lens
    Àΰø¼öÁ¤Ã¼
  • objective lens
    ´ë¹°·»Áî
  • oxygen consumption
    »ê¼Ò¼Ò¸ð
  • oxygen content
    »ê¼ÒÇÔÀ¯·®
  • fraction in inspired oxygen
    ÈíÀÔ»ê¼Ò³óµµ
  • oxygen fraction in inspired air
    ÈíÀÔ»ê¼Ò³óµµ
  • oxygen
    »ê¼Ò
  • active oxygen
    Ȱµ¿»ê¼Ò, Ȱ¼º»ê¼Ò
  • hyperbaric oxygen
    °í¾Ð»ê¼Ò
  • saturation dissolved oxygen
    Æ÷È­¿ëÇØ»ê¼Ò·®
  • oxygen requirement
    »ê¼Ò¿ä±¸·®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gas permeable lens
    °¡½ºÅõ°ú·»Áî, »ê¼ÒÅõ°ú·»Áî
  • permeable membrane
    Åõ°ú¸·
  • permeable
    Åõ°ú-
  • active oxygen
    Ȱµ¿»ê¼Ò, Ȱ¼º»ê¼Ò
  • alveolar oxygen pressure
    ÆóÆ÷»ê¼Ò¾Ð
  • alveolar-arterial oxygen gradient
    ÆóÆ÷µ¿¸Æ°£»ê¼ÒºÐ¾ÐÂ÷
  • arterial oxygen saturation
    µ¿¸ÆÇ÷»ê¼ÒÆ÷È­µµ
  • arterial oxygen tension
    µ¿¸ÆÇ÷»ê¼ÒºÐ¾Ð
  • oxygen aeration
    »ê¼ÒÅë±â
  • oxygen apnea
    »ê¼Ò¹«È£Èí
  • biochemical oxygen demand
    »ý¹°È­ÇÐÀû»ê¼Ò¿ä±¸·®
  • biological oxygen demand
    »ý¹°ÇÐÀû»ê¼Ò¿ä±¸·®
  • chemical oxygen demand
    È­Çлê¼Ò¿ä±¸·®
  • compressed oxygen
    ¾ÐÃà»ê¼Ò
  • mean venous oxygen content
    Æò±ÕÁ¤¸ÆÇ÷»ê¼Ò·®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gas permeable lens
    °¡½ºÅõ°ú·»Áî, »ê¼ÒÅõ°ú·»Áî
  • advanced glycosylation end products
    ÁøÇ༺´çÈ­Á¾¸»»ý¼º¹°(òäú¼àõÓÐûùðûØÇßæà÷Úª)
  • grain products
    ¿¡¤Á°î·ùÁ¦Ç°.
  • BOD=ÊÝbiochemical oxygen demand
    »ý¹°È­ÇÐÀû »ê¼Ò¿ä±¸·®.
  • Helium-oxygen mixture
    Çï·ý»ê¼ÒÈ¥ÇÕü
  • Hemoglobin-oxygen equilibrium curve
    Çì¸ð±Û·Îºó-»ê¼Ò°î¼±
  • OER [=oxygen enhancement ratio]
    »ê¼Ò°­È­À²
  • PAO2 => alveolar oxygen pressure
    ÆóÆ÷(øËøà)»ê¼Ò¾Ð
  • So2=>oxygen saturation
    »ê¼ÒÆ÷È­µµ
  • active oxygen
    Ȱ¼º»ê¼Ò(üÀàõß«áÈ).
  • altered oxygen affinity
    »ê¼Òģȭ¼º º¯¼º
  • alveolar arterial oxygen gradient
    ÆóÆ÷µ¿¸Æ°£ »ê¼ÒºÐ¾ÐÂ÷.
  • alveolar-arterial oxygen difference
    ÆóÆ÷-µ¿¸Æ »ê¼ÒÂ÷ÀÌ
  • alveolar-arterial oxygen gradient
    ÆóÆ÷µ¿¸Æ°£ »ê¼ÒºÐ¾ÐÂ÷
  • arterial blood oxygen tension
    µ¿¸ÆÇ÷»ê¼Ò Àå·Â.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gas permeable lens
    °¡½ºÅõ°ú·»Áî, »ê¼ÒÅõ°ú·»Áî
  • permeable membrane
    Åõ°ú¸·(÷âΦد).
  • advanced glycosylation end products
    ÁøÇ༺´çÈ­Á¾¸»»ý¼º¹°(òäú¼àõÓÐûùðûØÇßæà÷Úª)
  • biological products
    »ý¹°ÇÐÀû Á¦Á¦(¡­ð²ð¥).
  • biological products
    »ý¹°ÇÐÀû Á¦Á¦(ÊÙ̡̡).
  • fibrin degradation products =fDP
    ¼¶À¯¼ÒºÐÇØ»ê¹°
  • fibrinogen degradation products=FDP
    ¼¶À¯¼Ò¿ø ºÐÇØ»ê¹°
  • grain products
    ¿¡¤Á°î·ùÁ¦Ç°.
  • marine products
    ÇØ»ê¹°(Ì´Ë×ËÑ).
  • retarder for gypsum products
    ¼®°í»ê¹°°æÈ­Áö¿¬Á¦(à´ÍÇß§ÚªÌãûùòÀæÅð¥).
  • active oxygen
    Ȱ¼º»ê¼Ò(üÀàõß«áÈ).
  • altered oxygen affinity
    »ê¼Òģȭ¼º º¯¼º
  • alveolar arterial oxygen gradient
    ÆóÆ÷µ¿¸Æ°£ »ê¼ÒºÐ¾ÐÂ÷.
  • alveolar-arterial oxygen difference
    ÆóÆ÷-µ¿¸Æ »ê¼ÒÂ÷ÀÌ
  • alveolar-arterial oxygen gradient
    ÆóÆ÷µ¿¸Æ°£ »ê¼ÒºÐ¾ÐÂ÷
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Lens
    ¼öÁ¤Ã¼
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼
  • Lens cavity
    ¼öÁ¤Ã¼°ø°£
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼°­
  • Lens pore
    ¼öÁ¤Ã¼±¸¸Û
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼°ø
  • Lens placode
    ¼öÁ¤Ã¼±â¿øÆÇ
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼ÆÇ
  • Lens radius
    ¼öÁ¤Ã¼³¯ÁÙ
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼°æ
  • Lens artery
    ¼öÁ¤Ã¼µ¿¸Æ
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼µ¿¸Æ
  • Vascular layer of lens
    ¼öÁ¤Ã¼¸Æ°üÃþ
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼¸Æ°üÃþ
  • Lens substance
    ¼öÁ¤Ã¼¹°Áú
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼Áú
  • Fovea of lens
    ¼öÁ¤Ã¼¿À¸ñ
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼¿Í
  • Lens fovea
    ¼öÁ¤Ã¼¿À¸ñ
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼¿Í
  • Equator of lens
    ¼öÁ¤Ã¼Àûµµ
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼Àûµµ
  • Axis of lens
    ¼öÁ¤Ã¼Ãà
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼Ãà
  • Capsule of lens
    ¼öÁ¤Ã¼ÇǸ·
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼ÇǸ·
  • Lens capsule
    ¼öÁ¤Ã¼ÇǸ·
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼ÇǸ·
  • Superficial lens epithelium
    ¾èÀº¼öÁ¤Ã¼»óÇÇ
    [¿¾ ¿ë¾î] õ¼öÁ¤Ã¼»óÇÇ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • collimating lens
    ÆòÇüÈ­(øÁû¬ûù) ·»Áî
  • biochemical oxygen demand
    »ýÈ­ÇÐÀû(ßæûùùÊîÜ) »ê¼Ò¿ä±¸·®(ß«áÈé©Ï´Õá)
  • biological oxygen demand
    »ý¹°ÇÐÀû »ê¼Ò¿ä±¸·®(ßæÚªùÊîÜß«áÈé©Ï´Õá)
  • carbon-oxygen cycle
    ź¼Ò»ê¼Ò ȸ·Î(÷©áÈß«áÈüÞÖØ)
  • cytochrome c : oxygen oxidoreductase
    »çÀÌÅäÅ©·Ò c »ê¼Ò(ß«áÈ) ¿Á½Ãµµ¸®´öÅ×À̽º (ÔÒ) complex IV
  • oxygen
    »ê¼Ò(ß«áÈ)
  • oxygen carrier
    »ê¼Ò ¿î¹Ýü(ß«áÈê¡Úæô÷)
  • oxygen combining power
    »ê¼Ò°áÇÕ´É(úìäûß«áÈÌ¿ùêÒö)
  • oxygen cycle
    »ê¼Òȸ·Î(ß«áÈüÞÖØ)
  • oxygen debt
    »ê¼ÒºÎä(ß«áÈݶóð)
  • oxygen dissociation curve
    »ê¼ÒÇØ¸®°î¼±(ß«áÈú°×îÍØàÊ)
  • oxygen electrode
    »ê¼ÒÀü±Ø(ß«áÈï³Ð¿)
  • oxygen saturation
    »ê¼ÒÆ÷È­(ß«áÈøéûú)
  • oxygen saturation curve
    »ê¼ÒÆ÷È­°î¼±(ß«áÈøéûúÍØàÊ)
  • oxygen transferase
    "»ê¼Ò Æ®·£½ºÆÛ·¹À̽º, »ê¼ÒÀüÀÌÈ¿¼Ò(ß«áÈï®ì¹ý£áÈ)"
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • oxygen
    »ê¼Ò
  • oxygen free radical
    »ê¼ÒÀÚÀ¯±â
  • acoustic lens
    À½Çâ·»Áî
  • biconvex lens
    ¾ç¸éº¼·Ï·»Áî
  • concave lens
    ¿À¸ñ·»Áî
  • lens
    ¼öÁ¤Ã¼, ·»Áî
  • wide angle lens
    ±¤°¢·»Áî
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
FDP(s)   1) Fibrinolytic split Products(= FSP)
  2) Fibrinogen Degradation Products
FSP familial spastic paraplegia; fibrin split products; fibrinogen split products; fine suspended partic...
misc miscarriage; miscellaneous
CGRPs Calcitonin Gene-Related Products
CPSC congenital paucity of secondary synaptic clefts [syndrome]; Consumer Products Safety Commission
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
RGP Rigid Gas Permeable
BLEC bovine lens epithelial cell
CL Contact Lens
HLE Human lens epithelial
IOL Intra Ocular Lens
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • advanced glycosylation end products
    ÁøÇ༺ ´çÈ­ Á¾¸» »ý¼º¹°
  • alveolar arterial oxygen gradient
    ÆóÆ÷µ¿¸Æ°£ »ê¼Ò ºÐ¾ÐÂ÷
  • alveolar-arterial oxygen difference
    ÆóÆ÷-µ¿¸Æ »ê¼Ò Â÷ÀÌ
  • biochemical oxygen demand
    »ý¹°È­ÇÐÀû »ê¼Ò ¿ä±¸, »ý¹°È­ÇÐÀû »ê¼Ò ¿ä±¸·®
  • bridging oxygen atom
    °¡±³ »ê¼Ò
    2°³ÀÇ ±Û¶ó½º Çü¼º ¿øÀÚ¸¦ ¿¬°áÇÏ´Â »ê¼Ò.
  • chemical oxygen demand
    È­ÇÐÀû »ê¼Ò ¿ä±¸·®
  • hyperbaric oxygen chamber
    °í¾Ð »ê¼Ò½Ç
    °í¾ÐÀÇ »ê¼Ò¸¦ ÀÌ¿ëÇØ Àú»ê¼ÒÁõÀ» Ä¡·áÇϱâ À§ÇÑ ÀåÄ¡.
  • maximum oxygen consumption
    ÃÖ´ë »ê¼Ò ¼Ò¸ð·®
  • oxygen
    »ê¼Ò
    Æó¿¡¼­ Ç÷·ù·Î µé¾î°¡ »ýüÀÇ ¸ðµç ¼¼Æ÷¿¡ ¿î¹ÝµÇ´Â °¡½º.
  • oxygen affinity
    »ê¼Ò ģȭ¼º
  • oxygen balance
    »ê¼Ò ÆòÇü
  • oxygen carrier
    »ê¼Ò ¿î¹Ýü
  • oxygen coefficient
    »ê¼Ò °è¼ö
  • oxygen demand
    »ê¼Ò ÇÊ¿ä, »ê¼Ò Çʿ䷮, »ê¼Ò ¿ä±¸·®
  • oxygen deprivation
    »ê¼Ò °áÇÌ, »ê¼Ò ºÎÁ·
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
permeable Capable of being permeated, or passed through; yielding passage; passable; penetrable; used especially of substances which allow the passage of fluids; as, wood is permeable to oil; glass is permeable to light.
Origin: L. Permeabilis: cf. F. Permeable. See Permeate.
Source: Websters Dictionary
(01 Mar 1998)
biological products Complex pharmaceutical substances, preparations, or agents of organic origin, usually obtained by biological methods or assay, that depend for their action on the processes affecting immunity. They are used especially in diagnosis and treatment of disease (as vaccines or pollen extracts). Biological products are differentiated from biological factors in that the latter are compounds with biological or physiological activity made by living organisms.
(12 Dec 1998)
blood products Biopharmaceutical products purified from human blood, such as the blood clotting factor VIII used to treat haemophiliacs. (Recombinant factor VIII is also on the market.) The term also refers to biopharmaceuticals that act on blood or the cells that make blood. These products are often produced by the cells themselves, but in such tiny amounts that extracting them from blood is impractical, and so they are genetically engineered.
(14 Nov 1997)
gene products, env Retroviral proteins, often glycosylated, coded by the envelope (env) gene. They are usually synthesised as protein precursors (polyproteins) and later cleaved into the final products by a viral protease.
(12 Dec 1998)
gene products, gag Proteins coded by the retroviral gag gene. The products are usually synthesised as protein precursors or polyproteins, which are then cleaved by viral proteases to yield the final products. Many of the final products are associated with the nucleoprotein core of the virion. Gag is short for group-specific antigen.
(12 Dec 1998)
gene products, nef Products of the HIV nef gene (formerly 3'-orf gene). The products trans-suppress viral replication and function as negative regulators of transcription. Nef stands for negative factor.
(12 Dec 1998)
gene products, pol Retroviral proteins coded by the pol gene. Often synthesised as a gag-pol fusion protein (fusion proteins, gag-pol) and later cleaved into final products that include reverse transcriptase, endonuclease/integrase, and viral protease. Pol is short for polymerase, the enzyme class of reverse transcriptase.
(12 Dec 1998)
gene products, rev Trans-acting nuclear proteins whose functional expression are required for HIV viral replication. Specifically, the rev gene products are required for processing and translation of the HIV gag and env mRNAs, and thus rev regulates the expression of the viral structural proteins. Rev can also regulate viral regulatory proteins. A cis-acting antirepression sequence (car) in env, also known as the rev-responsive element (rre), is responsive to the rev gene product. Rev is short for regulator of virion.
(12 Dec 1998)
gene products, rex Post-transcriptional regulatory proteins required for the accumulation of mRNAs that encode the gag and env gene products in HTLV-I and HTLV-II. The rex (regulator x; x is undefined) products act by binding to elements in the ltr.
(12 Dec 1998)
gene products, tat Trans-acting transcription factors. Nuclear proteins whose expression is required for HIV viral replication. The tat protein stimulates HIV-ltr-driven RNA synthesis for both viral regulatory and viral structural proteins. Tat stands for trans-activation of transcription.
(12 Dec 1998)
gene products, tax Transcriptional trans-acting proteins of the promoter elements found in the long-terminal repeats (ltr) of HTLV-I and HTLV-II. The tax (trans-activator x; x is undefined) proteins act by binding to enhancer elements in the ltr.
(12 Dec 1998)
gene products, vif A 23 kD regulatory protein important for virion infectivity in HIV. The protein is found in the cytoplasm of HIV-infected cells and is not absolutely required for virion formation.
(12 Dec 1998)
gene products, vpr Trans-acting proteins which accelerate virus replication in HIV. The vpr proteins act in trans to increase the levels of HIV specified proteins. Vpr is short for viral protein r, where r is undefined.
(12 Dec 1998)
gene products, vpu Non-glycosylated, membrane-associated, 16 kD proteins which are expressed in large amounts in cells infected with HIV-1. The proteins are required for efficient virion maturation and release. They are not present in HIV-2 nor in siv. Vpu is short for viral protein u, with u undefined.
(12 Dec 1998)
meat products Articles of food which are derived by a process of manufacture from any portion of carcasses of any animal used for food (e.g., head cheese, sausage, scrapple).
(12 Dec 1998)
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 1 ÆäÀÌÁö: 1
  • Oxygen Permeable Lens Products Misc - »õâ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • permeable
    ħÅõÇÒ ¼ö ÀÖ´Â
  • dairy products
    ³«³ó Á¦Ç°;À¯Á¦Ç°
  • marine products
    ÇØ»ê¹°
  • permeable
    »ïÅõ(ħÅõ,Åõ°ú)ÇÒ ¼ö ÀÖ´Â;Åõ°ú¼º(»ïÅõ¼º)ÀÇ
  • primary products
    ³ó»ê¹°
  • semi permeable
    ¾à°£ ±ÍÁßÇÑ;ÁØ º¸¼®ÀÇ
  • heavy oxygen
    Áß»ê¼Ò
  • hyperbaric oxygen therapy
    °í³óµµ »ê¼Ò ¿ä¹ý(ÀÏ»êȭź¼Ò Áßµ¶,³úÁ¹Áõ,´Ù¹ß¼º °æÈ­Áõ µî¿¡ »ç¿ëµÊ)
  • oxygen
    »ê¼Ò
  • oxygen debt
    »ê¼Òä
  • oxygen mask
    »ê¼Ò ¸¶½ºÅ©
  • oxygen tent
    »ê¼Ò ÅÙÆ®
  • lens
    ·»Áî
  • contact lens
    ÄÜÅÃÆ® ·»Áî
  • crown lens
    Å©¶ó¿î À¯¸® ·»Áî
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á